RxDoctor Payments Data

Holly Stebel

Optometrist · Boise, IDNPI 1982654612

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.8%), travel and lodging and other — rather than concentrated in one kind of arrangement. Alcon accounts for 77.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $2,242 and has fallen 93.6% since, to $144 in 2025. Among optometrist clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,321in general payments, 2019–2025

Across 40 payments — averaging $83.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Optos, Inc.$417
  • Biotissue Holdings Inc.$181
  • Sight Sciences, Inc.$84
  • ABB Con-cise Optical Group LLC$18
  • Astellas Pharma US Inc$17
  • plus $29 from 2 others

What the payments were for

  • Travel & lodging$1,31740%
  • Food & beverage$1,58748%
  • Other$41713%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,321 in reported general payments places this provider in the 90th percentile of 304 optometrist providers in Idaho.

See all optometrist providers in Idaho

Medicare billing

Part B allowed, 2024
$14,509
Medicare patients
80
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$202
Latanoprost17$199

Paid to pharmacies, not to this prescriber.

Other optometrist in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →